Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
FGFR1 overexpression
i
Other names:
FGFR1, BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM, Fibroblast growth factor receptor 1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
2260
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
FGFR1 fusion (6)
ZMYM2-FGFR1 fusion (5)
FGFR1OP2-FGFR1 fusion (3)
BCR-FGFR1 fusion (2)
BAG4-FGFR1 B2F6 (1)
FGFR1-G3BP2 fusion (1)
FGFR1-PLAG1 fusion (1)
FGFR1-TACC1 fusion (1)
FGFR1 fusion (6)
ZMYM2-FGFR1 fusion (5)
FGFR1OP2-FGFR1 fusion (3)
BCR-FGFR1 fusion (2)
BAG4-FGFR1 B2F6 (1)
FGFR1-G3BP2 fusion (1)
FGFR1-PLAG1 fusion (1)
FGFR1-TACC1 fusion (1)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
FGFR1 overexpression
Urothelial Cancer
FGFR1 overexpression
Urothelial Cancer
atezolizumab + BAY 1163877
Sensitive: C2 – Inclusion Criteria
atezolizumab + BAY 1163877
Sensitive
:
C2
atezolizumab + BAY 1163877
Sensitive: C2 – Inclusion Criteria
atezolizumab + BAY 1163877
Sensitive
:
C2
FGFR1 overexpression
Renal Cell Carcinoma
FGFR1 overexpression
Renal Cell Carcinoma
sorafenib
Resistant: C3 – Early Trials
sorafenib
Resistant
:
C3
sorafenib
Resistant: C3 – Early Trials
sorafenib
Resistant
:
C3
FGFR1 overexpression
Lung Cancer
FGFR1 overexpression
Lung Cancer
ponatinib
Resistant: C3 – Early Trials
ponatinib
Resistant
:
C3
ponatinib
Resistant: C3 – Early Trials
ponatinib
Resistant
:
C3
FGFR1 overexpression
Lung Non-Small Cell Squamous Cancer
FGFR1 overexpression
Lung Non-Small Cell Squamous Cancer
BAY 1163877
Resistant: C3 – Early Trials
BAY 1163877
Resistant
:
C3
BAY 1163877
Resistant: C3 – Early Trials
BAY 1163877
Resistant
:
C3
FGFR1 overexpression
Urothelial Cancer
FGFR1 overexpression
Urothelial Cancer
BAY 1163877
Sensitive: C3 – Early Trials
BAY 1163877
Sensitive
:
C3
BAY 1163877
Sensitive: C3 – Early Trials
BAY 1163877
Sensitive
:
C3
FGFR1 overexpression
Hormone Receptor Positive Breast Cancer
FGFR1 overexpression
Hormone Receptor Positive Breast Cancer
palbociclib + BAY 1163877
Sensitive: C3 – Early Trials
palbociclib + BAY 1163877
Sensitive
:
C3
palbociclib + BAY 1163877
Sensitive: C3 – Early Trials
palbociclib + BAY 1163877
Sensitive
:
C3
FGFR1 overexpression
Non Small Cell Lung Cancer
FGFR1 overexpression
Non Small Cell Lung Cancer
M6123
Sensitive: D – Preclinical
M6123
Sensitive
:
D
M6123
Sensitive: D – Preclinical
M6123
Sensitive
:
D
FGFR1 overexpression
HER2 Negative Breast Cancer
FGFR1 overexpression
HER2 Negative Breast Cancer
alpelisib
Resistant: D – Preclinical
alpelisib
Resistant
:
D
alpelisib
Resistant: D – Preclinical
alpelisib
Resistant
:
D
FGFR1 overexpression
Hepatocellular Cancer
FGFR1 overexpression
Hepatocellular Cancer
lenvatinib
Resistant: D – Preclinical
lenvatinib
Resistant
:
D
lenvatinib
Resistant: D – Preclinical
lenvatinib
Resistant
:
D
FGFR1 overexpression
Liposarcoma
FGFR1 overexpression
Liposarcoma
erdafitinib
Resistant: D – Preclinical
erdafitinib
Resistant
:
D
erdafitinib
Resistant: D – Preclinical
erdafitinib
Resistant
:
D
FGFR1 overexpression
Gastric Cancer
FGFR1 overexpression
Gastric Cancer
infigratinib
Sensitive: D – Preclinical
infigratinib
Sensitive
:
D
infigratinib
Sensitive: D – Preclinical
infigratinib
Sensitive
:
D
FGFR1 overexpression
Non Small Cell Lung Cancer
FGFR1 overexpression
Non Small Cell Lung Cancer
anlotinib
Sensitive: D – Preclinical
anlotinib
Sensitive
:
D
anlotinib
Sensitive: D – Preclinical
anlotinib
Sensitive
:
D
FGFR1 overexpression
Lung Non-Small Cell Squamous Cancer
FGFR1 overexpression
Lung Non-Small Cell Squamous Cancer
PRN1371
Sensitive: D – Preclinical
PRN1371
Sensitive
:
D
PRN1371
Sensitive: D – Preclinical
PRN1371
Sensitive
:
D
FGFR1 overexpression
Thyroid Gland Carcinoma
FGFR1 overexpression
Thyroid Gland Carcinoma
lenvatinib
Sensitive: D – Preclinical
lenvatinib
Sensitive
:
D
lenvatinib
Sensitive: D – Preclinical
lenvatinib
Sensitive
:
D
FGFR1 overexpression
Bladder Cancer
FGFR1 overexpression
Bladder Cancer
TKI258
Sensitive: D – Preclinical
TKI258
Sensitive
:
D
TKI258
Sensitive: D – Preclinical
TKI258
Sensitive
:
D
FGFR1 overexpression
Bladder Cancer
FGFR1 overexpression
Bladder Cancer
PD173074
Sensitive: D – Preclinical
PD173074
Sensitive
:
D
PD173074
Sensitive: D – Preclinical
PD173074
Sensitive
:
D
FGFR1 overexpression
Breast Cancer
FGFR1 overexpression
Breast Cancer
FGFR inhibitor
Sensitive: D – Preclinical
FGFR inhibitor
Sensitive
:
D
FGFR inhibitor
Sensitive: D – Preclinical
FGFR inhibitor
Sensitive
:
D
FGFR1 overexpression
Breast Cancer
FGFR1 overexpression
Breast Cancer
palbociclib + ABSK091
Sensitive: D – Preclinical
palbociclib + ABSK091
Sensitive
:
D
palbociclib + ABSK091
Sensitive: D – Preclinical
palbociclib + ABSK091
Sensitive
:
D
FGFR1 overexpression
Breast Cancer
FGFR1 overexpression
Breast Cancer
palbociclib
Resistant: D – Preclinical
palbociclib
Resistant
:
D
palbociclib
Resistant: D – Preclinical
palbociclib
Resistant
:
D
FGFR1 overexpression
Cholangiocarcinoma
FGFR1 overexpression
Cholangiocarcinoma
NXP800
Sensitive: D – Preclinical
NXP800
Sensitive
:
D
NXP800
Sensitive: D – Preclinical
NXP800
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login